FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2205343352> ?p ?o ?g. }

• W2205343352 endingPage "8605" @default.
• W2205343352 startingPage "8605" @default.
• W2205343352 abstract "8605 Background: The use of interferon alfa in pts with FL has been associated with improved disease-free survival and in some cases overall survival in a number of randomized trials. Methods: A phase I/II trial of CHOP-rituximab followed by maintenance PegInt in pts with FL and no prior anthracycline-based therapy. Treatment consisted of R-CHOP (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 2 mg and prednisone 100 mg orally daily x 5 days) repeated at 21 day intervals for 6–8 cycles to a maximum response. Pts achieving at least a PR were assigned PegInt subcutaneously weekly for a planned 52 weeks individually dosed to maintain ≤ grade 2 toxicity profile. Results: Twenty seven pts were enrolled; four withdrew prior to receiving any therapy and one prior to receiving the first dose of PegInt. Twenty two pts were evaluable per protocol specifications. The median age of pts was 56 years (range 20–73). Nineteen patients had received no prior therapy; two patients had received one prior chemotherapy, and one patient had received prior radiation therapy. All patients who received at least one dose of PegInt were included in the analysis. Eighteen pts received 6 cycles of R-CHOP, and four pts received 8 cycles. The overall response rate to R-CHOP was 95% (complete response 15/22 or 68%; partial response 6/22 or 27% ). Fourteen pts (63%) completed 52 weeks of PegInt with the remainder stopping between 1 and 40 weeks because of toxicity. The median dose of PegInt tolerated by patients was 2.0 mcg/kg/wk. The most common toxicities (approximately 50% of patients each) from PegInt were fatigue, headache, anemia, neutropenia, and thrombocytopenia. Ten pts experienced grade 3 neutropenia at some point during therapy and the majority of toxicities otherwise were grade 1 or 2. With a median duration of follow-up for surviving pts of 34 months the 3 year probabilities of progression free and overall survival are 70% and 94% respectively. Conclusions: PegInt is feasible to administer in a maintenance fashion after R-CHOP in pts with FL. Pt willingness to accept grade 1–2 toxicities limited the number of pts who completed one year of therapy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Schering-Plough" @default.
• W2205343352 created "2016-06-24" @default.
• W2205343352 creator A5012375357 @default.
• W2205343352 creator A5043166717 @default.
• W2205343352 creator A5061471602 @default.
• W2205343352 creator A5072480385 @default.
• W2205343352 creator A5072808304 @default.
• W2205343352 creator A5078372000 @default.
• W2205343352 creator A5080338566 @default.
• W2205343352 creator A5081660118 @default.
• W2205343352 date "2008-05-20" @default.
• W2205343352 modified "2023-09-26" @default.
• W2205343352 title "Rituximab-CHOP (R-CHOP) plus maintenance pegylated interferon (PegInt) for patients (pts) with follicular lymphoma (FL) and no prior anthracycline-based therapy" @default.
• W2205343352 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.8605" @default.
• W2205343352 hasPublicationYear "2008" @default.
• W2205343352 type Work @default.
• W2205343352 sameAs 2205343352 @default.
• W2205343352 citedByCount "0" @default.
• W2205343352 crossrefType "journal-article" @default.
• W2205343352 hasAuthorship W2205343352A5012375357 @default.
• W2205343352 hasAuthorship W2205343352A5043166717 @default.
• W2205343352 hasAuthorship W2205343352A5061471602 @default.
• W2205343352 hasAuthorship W2205343352A5072480385 @default.
• W2205343352 hasAuthorship W2205343352A5072808304 @default.
• W2205343352 hasAuthorship W2205343352A5078372000 @default.
• W2205343352 hasAuthorship W2205343352A5080338566 @default.
• W2205343352 hasAuthorship W2205343352A5081660118 @default.
• W2205343352 hasConcept C121608353 @default.
• W2205343352 hasConcept C126322002 @default.
• W2205343352 hasConcept C141071460 @default.
• W2205343352 hasConcept C2776694085 @default.
• W2205343352 hasConcept C2776755627 @default.
• W2205343352 hasConcept C2776802502 @default.
• W2205343352 hasConcept C2778283404 @default.
• W2205343352 hasConcept C2778720950 @default.
• W2205343352 hasConcept C2779338263 @default.
• W2205343352 hasConcept C2779429289 @default.
• W2205343352 hasConcept C2779725641 @default.
• W2205343352 hasConcept C2780653079 @default.
• W2205343352 hasConcept C530470458 @default.
• W2205343352 hasConcept C71924100 @default.
• W2205343352 hasConcept C90924648 @default.
• W2205343352 hasConceptScore W2205343352C121608353 @default.
• W2205343352 hasConceptScore W2205343352C126322002 @default.
• W2205343352 hasConceptScore W2205343352C141071460 @default.
• W2205343352 hasConceptScore W2205343352C2776694085 @default.
• W2205343352 hasConceptScore W2205343352C2776755627 @default.
• W2205343352 hasConceptScore W2205343352C2776802502 @default.
• W2205343352 hasConceptScore W2205343352C2778283404 @default.
• W2205343352 hasConceptScore W2205343352C2778720950 @default.
• W2205343352 hasConceptScore W2205343352C2779338263 @default.
• W2205343352 hasConceptScore W2205343352C2779429289 @default.
• W2205343352 hasConceptScore W2205343352C2779725641 @default.
• W2205343352 hasConceptScore W2205343352C2780653079 @default.
• W2205343352 hasConceptScore W2205343352C530470458 @default.
• W2205343352 hasConceptScore W2205343352C71924100 @default.
• W2205343352 hasConceptScore W2205343352C90924648 @default.
• W2205343352 hasIssue "15_suppl" @default.
• W2205343352 hasLocation W22053433521 @default.
• W2205343352 hasOpenAccess W2205343352 @default.
• W2205343352 hasPrimaryLocation W22053433521 @default.
• W2205343352 hasRelatedWork W160156331 @default.
• W2205343352 hasRelatedWork W1970150235 @default.
• W2205343352 hasRelatedWork W2023102849 @default.
• W2205343352 hasRelatedWork W2058154950 @default.
• W2205343352 hasRelatedWork W2075288748 @default.
• W2205343352 hasRelatedWork W2153978703 @default.
• W2205343352 hasRelatedWork W2888800187 @default.
• W2205343352 hasRelatedWork W4236815493 @default.
• W2205343352 hasRelatedWork W4244051174 @default.
• W2205343352 hasRelatedWork W434765413 @default.
• W2205343352 hasVolume "26" @default.
• W2205343352 isParatext "false" @default.
• W2205343352 isRetracted "false" @default.
• W2205343352 magId "2205343352" @default.
• W2205343352 workType "article" @default.